Objectives: Since biofilm formation is the hallmark of Enterococcus faecalis isolates, the aim of this study was to quantify biofilm formation in the presence of subinhibitory concentrations of tigecycline.
Introduction
Biofilm formation is an important factor in the pathogenesis of enterococcal infections, with Enterococcus faecalis producing biofilm more often than Enterococcus faecium. Enterococci in biofilms are more resistant to antibiotics than planktonically growing enterococci, thus the potential impact of biofilm formation could be clinically significant. A previous in vitro study determining minimum biofilm inhibitory concentrations showed that very high ampicillin, vancomycin and linezolid concentrations were required to inhibit enterococcal biofilms in vitro. 1 In an in vitro catheter-related bacteraemia model, the lack of linezolid and vancomycin activity against biofilm embedded organisms appeared as the primary reason for microbiological failure. 2 Resistance to antibiotics and to phagocytosis of cells embedded in biofilms frequently requires removal of the medical device, which may not always be possible, as the only appropriate cure of enterococcal biofilm-associated infections.
One of the major goals in modern clinical microbiology is the development of strategies capable of reducing biofilm infections, with compounds not only active against planktonic cells but also able to interfere with or decrease biofilm development. Since tigecycline exhibits the highest intrinsic activity among common antibiotics used against E. faecalis (MIC 90 ¼ 0.25 mg/L), 3 although with differences between MICs and MBCs (tolerance), the aim of this study was to quantify biofilm formation by E. faecalis in the presence of subinhibitory concentrations of tigecycline. (including the 6 E. faecium isolates) kindly supplied by Hospital Universitario Gregorio Marañó n (Madrid, Spain), were screened to assess their capability of biofilm production, following the methods described below. The 6 E. faecium strains had been isolated from peritoneal fluid (5 strains) and blood (1 strain), and the 50 E. faecalis strains had been isolated from urine (25 strains), blood (22 strains), intra-abdominal abscess (1 strain), catheter (1 strain) and sputum (1 strain 
Materials and methods

Strains
Susceptibility testing
The MICs of tigecycline were determined three times by microdilution following CLSI recommendations. 4 Modal values were considered.
Biofilm production
Biofilm production was spectrophotometrically assessed 5 using 96-well polystyrene microtitre plates (Masterlab S.L., Madrid, Spain). Bacterial suspensions in tryptic soy broth (TSB; Pronadisa, Torrejó n de Ardoz, Madrid, Spain) supplemented with 1% glucose (turbidity equivalent to that of a 0.5 McFarland standard) were used. Wells (0.2 mL) were inoculated with 0.15 mL of bacterial suspensions and 0.05 mL of supplemented TSB containing the corresponding tigecycline concentrations or supplemented TSB without antibiotic (antibiotic-free controls). Final tigecycline concentrations in the 0.2 mL samples were 0.25× MIC or 0.5× MIC for the strains tested. Plates were covered and incubated (378C, 5% CO 2 ) for 24 h. Afterwards, the contents of each well were removed by decanting, and the wells were washed with sterile distilled water. The empty wells were allowed to dry for 30 min, then 0.2 mL of Crystal Violet (25%) stain was added to each well. After 5 min, excess stain was rinsed off by decanting, and the plate was washed. After the well had been allowed to dry for 30 min, 0.2 mL of 25% HCl was added to each well, and, after 1 min, the ODs of stained adherent bacterial films were read using a Micro-ELISA auto-reading spectrophotometer (Labsystems Multiskan, Helsinki, Finland) at 450 nm. E. faecalis ATCC 29212 was used as positive control (strong producer, OD 450 ¼0.611), and non-bacterial-inoculated wells were used as negative controls (OD 450 ¼0.055). Experiments with each strain were performed 12 times.
Statistical analysis
For each strain, median (IQR) values were calculated from the OD 450 values obtained in the absence and presence of tigecycline. OD 450 values from antibiotic-free medium and tigecycline-containing medium were compared individually and globally (all 20 strains) using the Wilcoxon test. The comparison between OD 450 values obtained with urinary strains and those with strains from blood was performed by the Mann-Whitney test. In addition, per-strain percentages of reduction in median OD 450 in the presence of tigecycline versus controls (antibioticfree wells) were calculated.
Results
All E. faecium isolates tested in the screening phase were biofilm non-producers (4 isolates) or weak producers (2 isolates). Among the screened 50 E. faecalis isolates, 1 (2%) was a non-producer, 23 (46%) were weak producers, 15 (30%) were moderate producers and 11 (22%) were strong producers. The 11 strong producers and the 9 moderate producers with the highest OD 450 values obtained in the screening phase were chosen for the study. Table 1 
Discussion
E. faecalis causes 85% -90% of enterococcal infections and the remaining are caused by E. faecium where acquisition of genes encoding resistance to penicillin, aminoglycosides (high level) and glycopeptides is a cause of concern. In contrast, resistance in E. faecalis is mainly functional (phenotypic) because virtually all isolates produce biofilm, and cells embedded in biofilms are highly resistant to antibiotics due to restricted penetration of antimicrobials, heterogeneous metabolic activity, different gene expression patterns compared with planktonic cells and cell-to-cell communication systems.
In the screening phase of the present study, 98% of E. faecalis isolates produced biofilm to varying degrees (54.2% moderate or strong producers), whereas only 33.4% of E. faecium isolates were biofilm producers (weak). Biofilm production is the hallmark of E. faecalis, with isolates from intravascular-catheter-related infections producing more biofilm. 6 A previous study that tested 352 isolates from urinary tract infections showed that all isolates produced biofilm. 7 In the present study, significantly higher biofilm formation (higher OD 450 in antibiotic-free controls) was measured when testing isolates from urine than those from blood. Different studies have identified several environmental, phenotypic and genetic factors associated with E. faecalis biofilm production; however, much more research is needed for a better understanding of the regulation of biofilm production.
Once the biofilm is completely developed, conventional antibiotic treatments fail to eradicate the biofilm layers, 2 and very high enterococcal-biofilm-eradicating concentrations (not achievable in vivo) are required. 1 Due to this, strategies aimed at preventing biofilm formation acquire importance. In the present study, we investigated the ability of tigecycline to interfere with biofilm formation using physiological subinhibitory tigecycline concentrations. MICs of tigecycline for the 20 studied E. faecalis strains were in the upper range of susceptibility (0.12 or 0.25 mg/L) according to EUCAST and BSAC breakpoints (≤0.25 mg/L). The tigecycline concentrations used were similar to trough concentrations in serum (0.06 mg/L) after the standard dose, 8 or to concentrations in the colon (0.10 mg/L) using a penetration rate (AUC colon /AUC serum ) of 1.73. 9 Using these concentrations significantly lower biofilm formation was observed when tigecycline was present in the medium: reductions .20% in 11 of 20 (55%) strains with 0.5× MIC tigecycline concentrations, and in 17 of 20 (85%) with 0.25× MIC. However, the reason for the significantly greater reduction obtained with 0.25× MIC than with 0.5× MIC for 5 studied strains remains to be explored since, in the present study, OD 450 reductions were not related to MICs or to the magnitude of biofilm formation in the absence of the antibiotic.
Enterococcal biofilms are important not only in intravascular catheters, biliary stent implants and gastrostomy devices, but also in the catheterized urinary tract; these provide ideal conditions for biofilm development, inducing complications in patient care. A previous animal model highlighted the potential benefit of tigecycline in preventing enterococcal ureteral stent infections. 10 The present study shows that tigecycline was able to interfere with biofilm formation in vitro by E. faecalis. Further studies exploring the activity of achievable supra-inhibitory concentrations in vivo against formed E. faecalis biofilms are warranted.
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